$GLYC

GlycoMimetics Inc

  • NASDAQ
  • Health Technology
  • Biotechnology
  • Manufacturing
  • Pharmaceutical Preparation Manufacturing

PRICE

$0.56 ▼-0.603%

Last Close

VOLUME

156,476

DAY RANGE

0.56 - 0.6

52 WEEK

0.51 - 2.5

Join Discuss about GLYC with like-minded investors

profile
@dros #droscrew
recently

Upgrades 11/12: $BBVA $CCLP $CGNX $GGB $GLYC $JRVR $PENN $RADI . Downgrades 11/12: $AFIB $BAM $BHG $CELH $EYE $FSM $GEF $GRWG $HOOK $HPE $KINS $NVDA $PSFE $RIDE SAN

123 Replies 10 👍 13 🔥

TR
@TraderJack #ivtrades
recently

New buy signal for $GLYC

68 Replies 7 👍 9 🔥

profile
@RedSunCap #droscrew
recently

3471 $GLYC Dec20 5.0 Calls trade $1.75

65 Replies 6 👍 6 🔥

profile
@ivtrades-Chris #ivtrades
recently

3471 $GLYC Dec20 5.0 Calls trade $1.75 (FT Theo=1.21) ASKSIDE PHLX 12:15:11 IV=158.1% FLOOR - OPENING Vol=3500, OI=99,

44 Replies 15 👍 12 🔥

Key Metrics

Market Cap

29.52 M

Beta

0.98

Avg. Volume

159.21 K

Shares Outstanding

52.39 M

Yield

0%

Public Float

0

Next Earnings Date

2022-08-04

Next Dividend Date

Company Information

GlycoMimetics is a biotechnology company with a focus in hematology-oncology and a pipeline of novel glycomimetic drugs, all designed to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics' drug candidate, uproleselan, an E-selectin antagonist, was evaluated in a Phase 1/2 clinical trial as a potential treatment for AML and is being evaluated across a range of patient populations including in a Company-sponsored Phase 3 trial in relapsed/refractory AML. GlycoMimetics has an ongoing Phase 1b clinical trial evaluating GMI-1359, a combined CXCR4 and E-selectin antagonist, also a wholly-owned drug candidate. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region.

CEO: Rachel King

Website:

HQ: 9708 Medical Center Dr Rockville, 20850-3343 Maryland

Related News